JP2010532387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532387A5 JP2010532387A5 JP2010515270A JP2010515270A JP2010532387A5 JP 2010532387 A5 JP2010532387 A5 JP 2010532387A5 JP 2010515270 A JP2010515270 A JP 2010515270A JP 2010515270 A JP2010515270 A JP 2010515270A JP 2010532387 A5 JP2010532387 A5 JP 2010532387A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- compound
- optionally substituted
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 103
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- -1 CH 2 F Chemical compound 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 238000007306 functionalization reaction Methods 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims description 2
- 125000004864 4-thiomethylphenyl group Chemical group 0.000 claims description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- MOZRQQTUYAYCQT-FQEVSTJZSA-N n-[[(3s)-3-amino-1-(5-ethyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-yl]methyl]-2,4-difluorobenzamide Chemical group C([C@]1(CCN(C1)C=1N=CN=C2NC=C(C=12)CC)N)NC(=O)C1=CC=C(F)C=C1F MOZRQQTUYAYCQT-FQEVSTJZSA-N 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 description 12
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94814707P | 2007-07-05 | 2007-07-05 | |
| US60/948,147 | 2007-07-05 | ||
| PCT/US2008/069147 WO2009006569A1 (en) | 2007-07-05 | 2008-07-03 | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013249824A Division JP2014040489A (ja) | 2007-07-05 | 2013-12-03 | Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010532387A JP2010532387A (ja) | 2010-10-07 |
| JP2010532387A5 true JP2010532387A5 (OSRAM) | 2012-07-26 |
| JP5542282B2 JP5542282B2 (ja) | 2014-07-09 |
Family
ID=39830222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515270A Active JP5542282B2 (ja) | 2007-07-05 | 2008-07-03 | Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン |
| JP2013249824A Withdrawn JP2014040489A (ja) | 2007-07-05 | 2013-12-03 | Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013249824A Withdrawn JP2014040489A (ja) | 2007-07-05 | 2013-12-03 | Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8377937B2 (OSRAM) |
| EP (2) | EP2404907B1 (OSRAM) |
| JP (2) | JP5542282B2 (OSRAM) |
| KR (2) | KR101624361B1 (OSRAM) |
| CN (1) | CN101918373B (OSRAM) |
| AT (1) | ATE522509T1 (OSRAM) |
| AU (1) | AU2008272832B2 (OSRAM) |
| BR (1) | BRPI0813993A2 (OSRAM) |
| CA (1) | CA2692506C (OSRAM) |
| ES (1) | ES2533557T3 (OSRAM) |
| IL (1) | IL202617A0 (OSRAM) |
| MX (1) | MX2009014013A (OSRAM) |
| SI (1) | SI2173723T1 (OSRAM) |
| WO (1) | WO2009006569A1 (OSRAM) |
| ZA (1) | ZA200908901B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0813999A2 (pt) * | 2007-07-05 | 2019-10-01 | Array Biopharma Inc | ciclopentanos de pirimidil como inibidores de akt proteína cinase |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| JP5608097B2 (ja) | 2008-01-08 | 2014-10-15 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害薬としてのピロロピリジン |
| AU2009204019B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
| US8372842B2 (en) | 2008-01-09 | 2013-02-12 | Array Biopharma Inc. | Pyrazolopyridines as kinase inhibitors |
| EP2250155B1 (en) | 2008-01-09 | 2013-07-03 | Array Biopharma, Inc. | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| GB201110546D0 (en) * | 2011-06-22 | 2011-08-03 | Imp Innovations Ltd | Compositions |
| ES2588878T3 (es) * | 2012-05-17 | 2016-11-07 | Array Biopharma, Inc. | Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| JP2019537585A (ja) | 2016-10-28 | 2019-12-26 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｅｚｈ２媒介性がんを治療するための組成物および方法 |
| CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| AU2019231689A1 (en) * | 2018-03-06 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
| JP2021527666A (ja) | 2018-06-21 | 2021-10-14 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法 |
| CN114423463B (zh) | 2019-05-06 | 2025-09-26 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| CN118530260A (zh) * | 2020-03-17 | 2024-08-23 | 江苏恒瑞医药股份有限公司 | 稠合二环类衍生物、其制备方法及其在医药上的应用 |
| CN113444110B (zh) * | 2020-03-25 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| US20250145641A1 (en) | 2021-09-17 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor |
| CN116514739B (zh) * | 2023-05-09 | 2025-07-22 | 天津绿菱气体股份有限公司 | 一种1,4-二甲基哌嗪及其制备方法 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3885035A (en) * | 1972-04-05 | 1975-05-20 | Sandoz Ag | Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines |
| US3956495A (en) * | 1973-10-30 | 1976-05-11 | Eli Lilly And Company | 2,4-Diaminoquinazolines as antithrombotic agents |
| US3966936A (en) * | 1974-02-21 | 1976-06-29 | Pfizer Inc. | Piperazino quinazoline bronchodilators |
| US4060615A (en) * | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
| JPS562968A (en) * | 1979-06-21 | 1981-01-13 | Mitsubishi Yuka Yakuhin Kk | Novel pyrimidine derivative |
| JPS6270A (ja) | 1985-03-07 | 1987-01-06 | Sankyo Co Ltd | シクロペンタ〔ｄ〕ピリミジン誘導体 |
| WO1990007926A1 (en) * | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
| DK0664291T3 (da) * | 1992-10-05 | 2000-10-30 | Ube Industries | Pyrimidinforbindelse |
| US5750545A (en) | 1993-07-23 | 1998-05-12 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
| GB9416189D0 (en) * | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
| JP2896532B2 (ja) * | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| US7067664B1 (en) * | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| ZA979961B (en) * | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| JP2002509536A (ja) | 1997-07-01 | 2002-03-26 | ワーナー−ランバート・カンパニー | ２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用 |
| US6506798B1 (en) * | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
| JP2002511092A (ja) | 1997-07-01 | 2002-04-09 | ワーナー−ランバート・コンパニー | ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用 |
| US6821963B2 (en) * | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| ES2356886T3 (es) * | 1998-03-31 | 2011-04-14 | Kyowa Hakko Kirin Co., Ltd. | Compuestos heterocíclicos nitrogenados. |
| DE19853278A1 (de) * | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CA2350234A1 (en) | 1999-01-07 | 2000-07-13 | Alexander James Bridges | Treatment of asthma with mek inhibitors |
| EP1140067A1 (en) | 1999-01-07 | 2001-10-10 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| EP1144371B1 (en) | 1999-01-13 | 2005-11-09 | Warner-Lambert Company Llc | Benzenesulphonamide derivatives and their use as mek inhibitors |
| ATE311363T1 (de) * | 1999-01-13 | 2005-12-15 | Warner Lambert Co | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren |
| IL144214A0 (en) * | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| AP2001002225A0 (en) * | 1999-01-13 | 2001-09-30 | Warner Lambert Co | 1-heterocycle substituted diarylamines. |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| HUP0202381A3 (en) | 1999-07-16 | 2004-12-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| CN1358094A (zh) | 1999-07-16 | 2002-07-10 | 沃尼尔·朗伯公司 | 用mek抑制剂治疗慢性疼痛的方法 |
| AU5786000A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
| IL153817A0 (en) | 2000-07-19 | 2003-07-31 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| MXPA03001654A (es) | 2000-08-25 | 2004-09-10 | Warner Lambert Co | Proceso para la elaboracion del acido n-aril-antranilico y sus derivados. |
| AU2001296871A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
| WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| DE60225127T2 (de) * | 2001-04-30 | 2009-02-19 | Glaxo Group Ltd., Greenford | Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf) |
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| CA2478534A1 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2478374C (en) * | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2003086279A2 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2003086403A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2003086394A1 (en) | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| US7273869B2 (en) | 2002-04-08 | 2007-09-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
| MXPA04011093A (es) * | 2002-05-10 | 2005-02-14 | Neurocrine Biosciences Inc | Piperazina sustituida como ligandos de receptores de melanocortina. |
| US7399764B2 (en) | 2002-10-30 | 2008-07-15 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| US20050045867A1 (en) * | 2002-10-30 | 2005-03-03 | Ozkan Cengiz S. | Nanoscale heterojunctions and methods of making and using thereof |
| EP1428793B1 (en) * | 2002-12-12 | 2011-02-09 | Sony Deutschland GmbH | Soluble carbon nanotubes |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US7638530B2 (en) | 2003-04-24 | 2009-12-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
| ATE440825T1 (de) * | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| AR045445A1 (es) | 2003-08-05 | 2005-10-26 | Vertex Pharma | Compuestos ihinibidores de canales ionicos regulados por voltaje |
| JP2007501821A (ja) * | 2003-08-12 | 2007-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｆｒアンタゴニストとしてのテトラヒドロキナゾリン誘導体 |
| BRPI0414238A (pt) * | 2003-09-09 | 2006-10-31 | Ono Pharmaceutical Co | antagonistas de crf e compostos heterobicìclicos |
| WO2005039564A1 (en) * | 2003-10-02 | 2005-05-06 | Vertex Pharmaceuticals Incorporated | Phthalimide compounds useful as protein kinase inhibitors |
| BRPI0416852A (pt) * | 2003-11-21 | 2007-02-27 | Array Biopharma Inc | inibidores da quinase akt |
| JP5213229B2 (ja) * | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| WO2005113762A1 (en) | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| US7556746B2 (en) * | 2004-06-03 | 2009-07-07 | Nantero, Inc. | Method of making an applicator liquid for electronics fabrication process |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| US7994172B2 (en) * | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| EP1858902A1 (en) | 2005-02-24 | 2007-11-28 | Pfizer Products Incorporated | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| RU2435769C2 (ru) * | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
| UY29610A1 (es) | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
| US20080004295A1 (en) | 2005-10-13 | 2008-01-03 | Gore Paul M | Novel compounds |
| JP2009523701A (ja) | 2005-12-28 | 2009-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| EP2013206A1 (en) | 2006-04-25 | 2009-01-14 | Astex Therapeutics Limited | Pharmaceutical compounds |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| GB0613518D0 (en) | 2006-07-06 | 2006-08-16 | Phytopharm Plc | Chemical compounds |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| SI2049478T1 (sl) | 2006-07-06 | 2012-08-31 | Glaxo Group Ltd | Substituirani N-fenilmetil-5-okso-prolin-2-amidi kot antagonisti receptorja P2X7 in postopki za njihovo uporabo |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| PL2049500T3 (pl) | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
-
2008
- 2008-07-03 EP EP11169324.8A patent/EP2404907B1/en active Active
- 2008-07-03 EP EP08781340.8A patent/EP2173723B3/en active Active
- 2008-07-03 AU AU2008272832A patent/AU2008272832B2/en not_active Ceased
- 2008-07-03 KR KR1020107002547A patent/KR101624361B1/ko not_active Expired - Fee Related
- 2008-07-03 CN CN2008801058708A patent/CN101918373B/zh active Active
- 2008-07-03 WO PCT/US2008/069147 patent/WO2009006569A1/en not_active Ceased
- 2008-07-03 JP JP2010515270A patent/JP5542282B2/ja active Active
- 2008-07-03 US US12/667,850 patent/US8377937B2/en active Active
- 2008-07-03 AT AT08781340T patent/ATE522509T1/de not_active IP Right Cessation
- 2008-07-03 ES ES11169324.8T patent/ES2533557T3/es active Active
- 2008-07-03 SI SI200830441T patent/SI2173723T1/sl unknown
- 2008-07-03 BR BRPI0813993-8A patent/BRPI0813993A2/pt not_active Application Discontinuation
- 2008-07-03 MX MX2009014013A patent/MX2009014013A/es not_active Application Discontinuation
- 2008-07-03 CA CA2692506A patent/CA2692506C/en not_active Expired - Fee Related
- 2008-07-03 KR KR1020157020348A patent/KR20150091196A/ko not_active Ceased
-
2009
- 2009-12-09 IL IL202617A patent/IL202617A0/en unknown
- 2009-12-14 ZA ZA2009/08901A patent/ZA200908901B/en unknown
-
2013
- 2013-12-03 JP JP2013249824A patent/JP2014040489A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532387A5 (OSRAM) | ||
| JP2009542721A5 (OSRAM) | ||
| JP2010532386A5 (OSRAM) | ||
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| JP2010524932A5 (OSRAM) | ||
| JP2014528433A5 (OSRAM) | ||
| JP2014503574A5 (OSRAM) | ||
| JP2011509309A5 (OSRAM) | ||
| JP2006509749A5 (OSRAM) | ||
| JP2006514626A5 (OSRAM) | ||
| JP2008501000A5 (OSRAM) | ||
| JP2006509000A5 (OSRAM) | ||
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| JP2017525737A5 (OSRAM) | ||
| JP2010241830A5 (OSRAM) | ||
| JP2011529054A5 (OSRAM) | ||
| JP2016507581A5 (OSRAM) | ||
| NO20071521L (no) | Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase | |
| JP2014506907A5 (OSRAM) | ||
| JP2009523760A5 (OSRAM) | ||
| CN112771045A (zh) | 喹啉并吡咯烷-2-酮类衍生物及其应用 | |
| JP2014507455A5 (OSRAM) | ||
| UA99447C2 (ru) | Способ получения силденафила | |
| JP2011509301A5 (OSRAM) | ||
| JP2011509302A5 (OSRAM) |